Renewal of the Hematology-Oncology Associates of Central New York (HOACNY) CCOP grant will enable us to continue to participate in NCI sponsored treatment and cancer control studies. We are currently following hundreds of patients on treatment trials and cancer control and prevention trials. Continuation of the grant will not only enable us to continue to follow these patients but to accrue additional individuals to such studies. Our clinical research department continues to work closely with the entire staff of HOACNY to identify eligible patients for treatment and symptom control studies. We actively recruit high-risk individuals from a large area of Central New York for cancer prevention studies. We have greatly expanded the participants in our CCOP (14 full time medical and radiation oncologists with 3 more to join soon), which will better serve our geographical region. The availability of a wide range of treatment and cancer control protocols improves the overall care of cancer patients in our community. The entire CCOP staff continues to not only provide "state of the art" care to our patients but also serves as a valuable resource to local health care providers and educates the entire CNY community in terms of cancer treatment and prevention. Our goal is to maintain the CCOP at a high level in terms of quantity and quality and to further increase our efforts in terms of cancer prevention.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Good, Marge
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Hematology-Oncology Associates/Ctl NY
East Syracuse
United States
Zip Code
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804
Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Solin, Lawrence J; Gray, Robert; Goldstein, Lori J et al. (2012) Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat 134:683-92
Hurria, Arti; Cirrincione, Constance T; Muss, Hyman B et al. (2011) Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 29:1290-6
Baer, M R; George, S L; Sanford, B L et al. (2011) Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-7

Showing the most recent 10 out of 49 publications